Inclusion Criteria:

          1. Women aged ≥18years and ≤70 years;

          2. At least on measurable disease according to the Response Evaluation Criteria in Solid
             Tumors (RECIST). Histologically confirmed invasive breast cancer, tumor size ≥2 cm,
             T2-4 N0-3M0;

          3. ER/PR/HER-2 and Ki-67 status detected on core biopsy. ER and/or PR positive was
             defined as >1% stained cells.HER2-positive is defined as immuno-histochemistry (IHC)
             3+ or the ratio of HER2 gene signals to chromosome 17 signals >2.0 or HER2 gene copy
             >6.0.

          4. No prior systemic or loco-regional treatment of breast cancer;

          5. Adequate bone marrow function:WBC≥4.0×109/L, Absolute neutrophil count（ANC）≥1.5×109/L,
             Platelets（PLT）≥100×109/L, Hemoglobin（Hb）≥90g/L;aspartate aminotransferase(AST),Alanine
             aminotransferase (ALT)≤1.5 upper normal limit (UNL), creatinine≤1.5 UNL,
             bilirubin≤1.5UNL;

          6. No obvious main organs dysfunction.

        Exclusion Criteria:

          1. Unwilling or unable to use an acceptable method of contraception in 8 weeks (including
             8 weeks) after final dose of test drug;

          2. Patient is pregnant or breast feeding;

          3. Inflammatory breast cancer and metastatic breast cancer;

          4. Any evidence of sense or motor nerve disorders;

          5. Patients with medical conditions taht indicate intolerant to neoadjuvant therapy,
             including uncontrolled cardiovascular disease, severe infection;

          6. Any concurrent malignancy other than breast cancer;

          7. Know severe hypersensitivity to any drugs in this study.